Featured Tickers:
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Amneal Pharmaceuticals, Inc. or Liquidia Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Amneal Pharmaceuticals, Inc. and Liquidia Corporation compare based on key financial metrics to determine which better meets your investment needs.
About Amneal Pharmaceuticals, Inc. and Liquidia Corporation
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson’s disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Latest Pharmaceuticals and Amneal Pharmaceuticals, Inc., Liquidia Corporation Stock News
As of August 12, 2025, Amneal Pharmaceuticals, Inc. had a $2.8 billion market capitalization, compared to the Pharmaceuticals median of $358.3 million. Amneal Pharmaceuticals, Inc.’s stock is up 13.9% in 2025, up 12% in the previous five trading days and up 16.09% in the past year.
Currently, Amneal Pharmaceuticals, Inc.’s price-earnings ratio is 820.0. Amneal Pharmaceuticals, Inc.’s trailing 12-month revenue is $2.9 billion with a 0.1% net profit margin. Year-over-year quarterly sales growth most recently was 3.2%. Analysts expect adjusted earnings to reach $0.767 per share for the current fiscal year. Amneal Pharmaceuticals, Inc. does not currently pay a dividend.
As of August 12, 2025, Liquidia Corporation had a $2.1 billion market cap, putting it in the 58th percentile of all stocks. Liquidia Corporation’s stock is up 104.9% in 2025, up 18.7% in the previous five trading days and up 111.78% in the past year.
Currently, Liquidia Corporation does not have a price-earnings ratio. Liquidia Corporation’s trailing 12-month revenue is $14.1 million with a -980.5% net profit margin. Year-over-year quarterly sales growth most recently was 3.3%. Analysts expect adjusted earnings to reach $-1.400 per share for the current fiscal year. Liquidia Corporation does not currently pay a dividend.
How We Compare Amneal Pharmaceuticals, Inc. and Liquidia Corporation Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Amneal Pharmaceuticals, Inc. and Liquidia Corporation’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions